WuXi Biologics, a global contract research, development, and manufacturing organization (CRDMO), launched a new bioprocessing platform WuXiUI, an ultra-intensified, fed-batch solution designed to enhance the productivity and quality of multiple different CHO or other mammalian cell lines and product modalities. To meet increasing demands for yield improvement, COGS reduction, and ESG consideration in the current bioprocess development, WuXi Biologics has developed WuXiUI, offering flexible an...